Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study
Shunji Takahashi(Japanese Foundation For Cancer Research), Noboru Yamamoto(Tokyo National Hospital), Tomonari Yamashita(Daiichi-Sankyo (Japan)), Takafumi Koyama(Tokyo National Hospital), Toshio Shimizu(Kansai Medical University), Kenji Nakano(The Cancer Institute Hospital), Sakura Sakajiri(Juntendo University Urayasu Hospital), Yutaka Fujiwara(Kobe University), Mariko Ogura(The Cancer Institute Hospital), Yasuyuki Kakurai(Daiichi-Sankyo (Japan)), Masaya Tachibana(Daiichi-Sankyo (Japan)), Junichi Tomomatsu(The Cancer Institute Hospital)
Cited by 72
Related Papers
E-CELL: software environment for whole-cell simulation.
|Bioinformatics|1999|765
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
|Clinical Cancer Research|2012|432